BRVEBraveheart Bio, Inc.

🇺🇸 US
30.00
USD
Analysis Scores
Lothien Robustness Score?
-
Neden bu skor?
Damodaran ?
-
Dalio Risk ?
-
Piotroski ?
N/A
Yetersiz çeyrek verisi: 4 mevcut, en az 5 gerekli
Graham ?
Veri Yetersiz
Özkaynaklar negatif veya sıfır — Graham formülü pozitif defter değeri gerektirir
Lothien Robustness Summary
43/100
Lothien Sağlamlık: Zayıf (43/100)
Olumsuz göstergeler ağır basıyor. Finansal yapıda zayıflıklar mevcut. | Kısa Vade: Olumlu | Uzun Vade: Olumsuz | Pozitif: 3 | Negatif: 3 | Nötr: 0
Net Zarar
Son çeyrekte -$15M zarar açıklandı. Yatırımcı dikkatli olmalı.
Çeyreklik Kâr Artışı
Net kâr bir önceki çeyreğe göre %+37.9 arttı (-$24M → -$15M). Kısa vadede olumlu momentum.
Yıllık Kâr Geriledi
Geçen yılın aynı dönemine göre net kâr %-3833.9 düştü. Uzun vadede endişe verici.
Net Nakit Pozisyonu
Şirketin nakdi borçlarından $122M fazla. Borç riski düşük.
Güçlü Likidite
Cari oran 13.63x — kısa vadeli borçları rahat karşılıyor.
Özkaynak Eriyor
Özkaynak çeyreklik %-22.3 düştü. Zarar veya temettü ile sermaye eriyor.

Data date date not measured Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date date not measured
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Valuation
Potential?
-
Balance Sheet Analysis? Q2026/9
Son 4 çeyrek ardışık zarar
Fiyat TRAMA-99 hafif altında: %+0.0
Direnç seviyesi: TRAMA-99 = 30.00 USD
Fundamental & Technical Analysis
Profitability
ROE - Return on Equity (TTM) %44.9
ROE %44.9 — high return on equity.
Valuation
No sector data
Indebtedness
Current Ratio 13.63x
Current ratio 13.63x — current assets are 2x short-term liabilities. Very healthy liquidity.
Debt / Equity -0.01x
Low leverage — majority of assets financed by equity.
Growth
Net Profit Growth (YoY) %-3833.9
Loss %3833.9 increased — losses deepening.
Score Explanations
Lothien Robustness
-
Good robustness (58/100). The company shows a generally balanced financial profile; some areas have room for improvement.
Dalio Risk Analysis
-
Low debt risk (74/100).
Leverage: 50/100 | Debt Service: 100/100 | Quality: 21/100
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
—
Graham Intrinsic Value
—
↔
TRAMA-99 Trend — Near TRAMA
Price (30.00), TRAMA-99 line (30.00) at close levels (%+0.0). Important decision zone — breakout direction will determine the trend.
Price:: 30.00
TRAMA: 30.00
Difference: %+0.0
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
▲ içeriden alım · ▼ içeriden satım · ★ katalizör (haber-sezgisel) · ■ 13D aktivist · ■ 13G pasif — SEC Form 4 ~2 gün gecikmeli, yalnız yönetici/direktör/%10+ sahip; katalizör = haber-sezgisel; 13D/G = %5+ pay bildirimi ~5 iş günü gecikmeli.
RSI (14) ?
Bollinger Bands ?
MACD ?

İçeriden Alım-Satım Akışı

Kim aldı, kim sattı, ne kadar

BRVE — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.